TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking individuals~* Diagnosed with non-insulin requiring type 2 diabetes~* Outpatients~* Baseline A1c of 7.5% or higher~Exclusion Criteria:~* Patients who are deemed unable to use a mobile phone (e.g. due to vision problems), and/or to comply with home monitoring (e.g. suffering from anxiety or depression)~* Diabetes duration \<1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): Mobile application plus standard of care
- Control Group (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Will CPAP Reduce Length Of Respiratory Support In Premature Infants?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants born greater than or equal to 28 weeks (28+0) and less than 32 weeks (31+6) gestation admitted to the NICU at a participating center~2. Diagnosis of RDS in the first 24 hours of life requiring intubation for surfactant administration by any combination of the following: Classic clinical signs of RDS include tachypnea, moderate to severe intercostal and subcostal retractions, grunting respirations and oxygen needs of \>0.30 and/or on CPAP of 5 to 6 H2O cm and/or radiographic signs of RDS including low lung volumes, a reticular-granular pattern of lung infiltrates and air bronchograms. A chest radiograph is not a mandatory criterion for the diagnosis of RDS if clinical signs are present~3. Parental consent obtained.~Exclusion Criteria:~1. Infants with a major congenital anomaly~2. Infants with pulmonary hypoplasia; 3. Infants known or suspected to have a neuromuscular disorder;~3. Infants from mothers that had greater than 2 weeks ruptured membranes.~4. Infants that had vigourous resuscitation including chest compressions and cardiac meds.~5. No parental consent obtained.

- Gender: ALL
- Minimum Age: 28 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Mechanical ventilation
- 2 (Type: EXPERIMENTAL): CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Study to Compare Noninvasive Ventilation (NIV) Masks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Already using overnight CPAP and tolerating the therapy well (over 4 hours use/night)~* Hypercapnia: venous bicarbonate of 30 milliequivalents of solute per liter (Eq/L) or more, OR transcutaneous carbon dioxide (TcCO2) of 50 millimeters of mercury (mmHg) of more.~* Provide written informed consent~* Already use a full (oronasal) face mask for CPAP~* Willing to have a venous blood sample taken during the pre-screening visit.~Exclusion Criteria:~* Presence of sleep apnea on CPAP:~  * Subjects excluded if they have an apnea-hypopnea index (AHI) of more than 20, or~ * If the AHI has not already decreased by 50 percent or more from pre-CPAP to with CPAP.~* Forced expiratory volume in 1 second (FEV1) of less than 40 percent of predicted.~* Forced expiratory volume in 1 second divided by forced vital capacity (FEV1/FVC) less than fifty percent of predicted, at the screening visit.~  * Have poorly controlled asthma or changing asthma symptoms.~ * Nasal obstruction~ * Do not fit Mask A or Mask B~ * Agitation or psychological illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Mask A (Type: EXPERIMENTAL): Overnight CPAP using the participant's usual pressure settings and using Mask A. One night only.
- Mask B (Type: ACTIVE_COMPARATOR): Overnight CPAP using the participant's usual pressure settings and using Mask B. One night only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. women with uncomplicated pregnancies and within 24 weeks of their last menstrual period~2. describe symptoms over the previous two weeks sufficient to meet DSM IV criteria for MDD as determined by the SCID~3. have a 21-item HAM-D of 16 or more~Exclusion Criteria:~1. antidepressant use in preceding month~2. use in previous 2 wks of non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics or glucocorticoids~3. use in previous 2 wks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than 2mg/day for insomnia~4. a previous diagnosis of an autoimmune disease, of hyperlipidemia, or of schizophrenia or schizoaffective disorder~5. evidence of substance dependence in previous 6 months~6. preoccupation with, or plans for, suicide~7. a history of hypersensitivity to fish or fish oil supplements~8. current use of anticoagulants~9. any current medical condition associated with clinically significant decreases in coagulability, i.e. systemic lupus erythematosis, VonWillebrend's disease~10. the initiation of regularly scheduled course of psychotherapy within the previous 2 months~11. current use of category D or category X medications

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Supplementation (Type: EXPERIMENTAL): Subjects received Omega-3 PUFA supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with moderately to severely active ulcerative colitis (UC) defined by a Mayo score of 6 to 12 inclusive at Baseline (Week 0), including an endoscopic (examination of an internal part of the body with a lighted tube; looking at a part of the body with a lighted tube) subscore of greater than or equal to 2~* Participants must have biopsy results (collected at the screening endoscopy (procedure or obtained within the last year) consistent with the diagnosis of UC~* Participants either currently receiving treatment with, or have a history of failure to respond to, or tolerate, at least 1 of the following therapies: oral 5-aminosalicylate (5-ASAs), oral corticosteroids, 6-mercaptopurine (6-MP) and azathioprine (AZA)~* Participants with current dependency or with a history of corticosteroid dependency (i.e. an inability to successfully taper corticosteroids without a return of the symptoms of UC) - Not have a diagnosis of active TB~Exclusion Criteria:~* Participants with previous exposure to biologic anti-tumor necrosis factor (TNF) agents~* Participants with severe extensive UC that is likely to require a colectomy (surgery to remove part or all of the colon) within 12 weeks of study entry~* Participants having UC limited to the rectum only or to less than 20 centimeter (cm) of the colon~* Presence of a stoma (an artificial permanent opening especially in the abdominal wall made in surgical procedures) or presence of a fistula~* Participants with a history of extensive colonic resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
- Golimumab 1 milligram (mg) per kilogram (kg) (Type: EXPERIMENTAL): Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
- Golimumab 2 mg per kg (Type: EXPERIMENTAL): Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
- Golimumab 4 mg per kg (Type: EXPERIMENTAL): Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with schizophrenia treated with clozapine; age 19-79~Exclusion Criteria:~* pregnant women, personal history of/or comorbid eating disorders

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Integrated care (Type: EXPERIMENTAL): Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
- Usual Care (Type: OTHER): Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has had rheumatoid arthritis for at least 6 months prior to the date of signing the informed consent at screening~* Must be positive for either anti-cyclic citrullinated peptide antibody or rheumatoid factor in serum at screening~* Must have active rheumatoid arthritis (at least 6 swollen and 6 tender joints using a 66/68 joint count at the time of screening and at baseline and Serum C reactive protein greater than or equal to 0.80 mg/dL at the time of screening~* Has been treated with and tolerated methotrexate treatment at dosages from 10 to 25 mg/week inclusive, for a minimum of 6 months with stable dose for at least 8 weeks prior to the date of signing the informed consent at screening~Exclusion Criteria:~* Has inflammatory diseases other than rheumatoid arthritis, including but not limited to adult onset Still's disease, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, and Lyme disease that might confound the evaluation of the benefit of study agent therapy~* Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive or uncontrolled~* Has ever received any approved or investigational biologic agent for a rheumatoid indication~* Has been treated with any nonbiologic disease modifying antirheumatic drugs within 4 weeks prior to the first administration of study agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- JNJ-38518168 (3 mg/d) (Type: EXPERIMENTAL): None
- JNJ-38518168 (10 mg/d) (Type: EXPERIMENTAL): None
- JNJ-38518168 (30 mg/d) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80.~2. Clinical diagnosis of cervical radicular pain.~3. Magnetic resonance imaging pathology consistent with clinical symptoms/signs.~4. Numerical Rating Scale (NRS) pain score of 4 or higher.~5. Pain duration of more than 6 weeks despite trial of conservative therapy (medications, physical therapy, or chiropractic care).~6. Patients who will undergo CESI for treatment of cervical radiculitis.~Exclusion Criteria:~1. Refusal to participate, provide consent, or provide communication and follow-up information for duration of the study.~2. Inability to perform handgrip or arm strength testing.~3. Contraindications to Cervical ESI (active infection, bleeding disorders, current anticoagulant or antiplatelet medication use, allergy to medications used for CIESI, and pregnancy).~4. Current glucocorticoid use or ESI within past 6 months.~5. Prior cervical spine surgery.~6. Cervical spinal cord lesions; cerebrovascular, demyelinating, or other neuro-muscular muscular disease.~7. Patient request for or requirement of conscious sedation for the injection procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- cervical interlaminar with lidocaine (Type: ACTIVE_COMPARATOR): Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
- cervical interlaminar with normal saline (Type: ACTIVE_COMPARATOR): Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~3.1.1 All postmenopausal women with histology-confirmed invasive primary breast cancer, who have completed primary surgical or radiotherapy (XRT) with or without adjuvant chemotherapy and are candidates to receive adjuvant therapy with aromatase inhibitors will be screened for eligibility. Postmenopausal is defined as satisfying one or more of the following criteria: having had bilateral oophorectomy; aged more than 60 years; or aged 55-59 years with an intact uterus and amenorrheic for at least 12 months; or if amenorrheic for less than 12 months (after receiving hysterectomy, hormone therapy or chemotherapy).~3.1.2 At the time of study enrollment, participants will have completed primary surgical or XRT with or without adjuvant chemotherapy. Chemotherapy will be completed at least 28 days prior to enrollment.~3.1.4 Participants will be women between 18-85 years of age. Women and minorities will be actively recruited. Though breast cancer extremely rarely occurs in children and men, this study will only recruit adult females.~3.1.5 Participants will have a life expectancy of at least 5 years.~3.1.6 Participants will have Eastern Clinical Oncology Group (ECOG) performance status 0-2.~3.1.7 Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~3.2.1 Medications affecting bone metabolism (bisphosphonates, anticonvulsants, chronic heparin therapy, chronic glucocorticoid use \> 5 mg/day prednisone or equivalent, teriparatide).~3.2.2 Use of any investigational drug within past 90 days.~3.2.3 Metastatic breast cancer. High risk for osteoporosis/fractures (BMD \< -2.0, history of non-traumatic fracture). Hyperparathyroidism Hypercalcemia Hypercalciuria (fasting spot urine calcium/creatinine ratio \>0.20) History of renal stones Renal failure with creatinine over 2.0~3.2.4 Considering that vitamin D3 is produced by the human body, allergy to vitamin D3 is not expected to develop. Subjects with known history of allergic reaction to compounds used to manufacture capsules (rice powder) will be excluded form this study.~3.2.5 Recent history of excessive alcohol or drug use.~3.2.6 As this study will recruit post-menopausal patients, thus pregnant or nursing patients are not part of this investigation.~3.2.8 This study is designed to study women after completing primary therapy for breast cancer. Survivors of previous cancers and HIV-positive subjects will not be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collagen Markers in Heart Failure and Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
- inclusion Signs of heart failure Elevated BNP EF \> 50% within 72 hours after admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- heart failure with preserved ejection fraction (Type: None): - Inclusion Elevated BNP EF \> 50%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Futility of Exhaled Breath Condensate pH Measurements in Ventilated Patients in Intensive Care Unit (ICU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Endotracheal intubation and mechanical ventilation for at least 48 hours due to non-pulmonary cause~* For whom their close acquaintances gave the informed consent~Exclusion Criteria:~* Pregnancy, denied surrogate decision-makers to give informed consent.~* Patients that required mechanical ventilation due to: pneumonia, severe respiratory infection, massive haemoptysis, acute severe asthma, bronchiectasis, COPD exacerbation, or acute lung injury. Finally, patients that expected to be ventilated less than 2 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBC pH (Type: None): Observational study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: 30 Day Rehospitalization Risk in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Must have been an existing patients of the outpatient dialysis units for at least 1 month prior to the index hospitalization~* Index hospitalization must be from an acute care hospital~Exclusion Criteria:~* Hospital discharges against medical advice~* Assessment cannot be initiated within 96 hours of hospital discharge~* Primary hospital diagnosis related to cancer, renal transplant, mental health or rehabilitation~* Hospital admission was the 5th or more in the previous 12 months~* Failure to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~\* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders.
- Usual care group (Type: NO_INTERVENTION): Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~\* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues